Company intelligence / Profile preview
Nterica Bio, Inc.
San Diego, California, United Statesnterica.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Currently conducting a Phase 1 clinical trial (NCT06750588) to evaluate the safety and tolerability of NTR-101 in patients with acute alcohol-associated hepatitis. The trial started on March 1, 2025, and is currently in the "Not yet recruiting" status[2][5].
- Therapeutic areas
- Gastroenterology
- Modalities
- Bacteriophage therapy
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Nterica Bio, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nterica Bio, Inc..